3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
No longer available
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Interventions
gallium 68 PSMA-11
2
carbon-11 acetate
2
Magnetic Resonance Spectroscopy
2
Axitinib
2
trametinib
1
tazemetostat
1
radium Ra 223 dichloride
1
pegilodecakin
1
omburtamab I-131
1
neratinib
1
bicalutamide
1
bemarituzumab
1
apalutamide
1
Suspensions
1
Standard of Care
1
Sodium Acetate
1
Prednisone
1
Prednisolone
1
Powders
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Paclitaxel
1
PSMA-11
1
N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid
1
MLN 8237
1
Everolimus
1
Androgen Antagonists
1
Abiraterone Acetate
1
AM0010
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
bemarituzumab
×
Genitourinary
×
Clear all
NCT03801278
2021-12-13
FPA144
Five Prime Therapeutics, Inc.
No longer available